TY - T1的疗效和安全性设置紧急颈动脉支架植入的急性缺血性中风(S02.002) JF -神经学乔-神经病学SP - S02.002 LP - S02.002六世- 80 - 7补充盟Fawaz Al-Mufti AU -坎迪斯帕金斯首页AU -穆汗盟Lissa脱皮AU -大卫程序Y1 - 2013/02/12 UR - //www.ez-admanager.com/content/80/7_Supplement/S02.002.abstract N2 -目的:回顾性描述紧急颈动脉支架的安全性和有效性在急性缺血性中风的设置与颅内血管再生。背景:中风二级颈内动脉(ICA)遮挡和preocclusive狭窄到静脉溶栓疗效很差。本研究描述了紧急颈动脉支架的安全性和有效性与颅内血管再生在急性缺血性中风。设计/方法:这是一个回顾性的图表总结评估患者的临床结果提交给石溪大学医院超过32个月。病人呈现在9小时内急性缺血性中风二级完成或功能的宫颈ICA闭塞或没有颅内栓子遮挡。病人紧急接受颈动脉支架植入其次是药理和/或机械颅内闭塞的血管再生。安全(没有出血症状和术后增加署和有效性(改进的署4分)进行评估。RESULTS: During the observed period,11 patients(6 females&5 males, mean age 65 years) presented to our hospital with acute stroke secondary to complete or functional cervical ICA occlusion with(n=6) or without(n=5) concomitant intracranial ICA and/or MCA occlusion. 5 patients had complete cervical ICA occlusions while 6 had pre-occlusive stenosis. Mean NIHSS score on admission was 15.2(range 8-22). Mean time from symptom onset to intervention was 4 hours 18 minutes. All patients were administered IA abciximab(dose range6-17mg,average 11.4mg) immediately following cervical ICA stenting. With regards to safety, no symptomatic hemorrhages were observed and no increase in their pre-procedural NIHSS was demonstrated. Upon discharge, the mean NIHSS score was 5.09 (range 0-17). Eight patients were discharged to acute rehabilitation facilities and three were discharged home. 10(90.9%)patients demonstrated an improvement in their presenting NIHSS by 4 points demonstrating an acceptable level of efficacy.CONCLUSIONS: The present data suggest that emergent carotid artery stenting in the setting acute ischemic stroke may be performed with an acceptable level of safety and efficacy.Disclosure: Dr. Al-Mufti has nothing to disclose. Dr. Perkins has received personal compensation for activities with Cardinal Health Bristol-Myers Squibb. Dr. Perkins holds stock and/or stock options in Pfizer. Dr. Perkins has received research support from Daiichi/Scirex, Astra Zeneca, Forest Research/Paion, Novo Nordisk, Sanofi-Aventis, and Garnett McKeen Labs. Dr. Khan has nothing to disclose. Dr. Peeling has nothing to disclose. Dr. Fiorella has received personal compensation for activities with Covidien/ev3, Codman/Micrus/JNJ, NFocus, Vascular Simulations, CSVL, Microvention/Terumo, Siemens Medical Imaging, and TD.Tuesday, March 19 2013, 1:00 pm-2:45 pm ER -